KromaTiD provides molecular and genetic testing solutions for detecting disease-causing mutations including inversions and translocations in a single assay. Based on its patented Directional Genomic Hybridization (dGH) technology, KromaTiD's assays generate sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies. Founded in 2007 and headquartered in Fort Collins, United States, the company has raised approximately $15.4M in Series C funding from investors including Broadoak Capital Partners and NHGRI. KromaTiD's research products and services support deeper understanding of genetic diseases including cancers and developmental disorders, serving pharmaceutical companies, research institutions, and clinical laboratories with high-resolution chromosomal analysis tools.
← All startups
KromaTiD
Series CKromaTiD provides molecular and genetic testing solutions for detecting disease-causing mutations including inversions and translocations in a single assay. Based on its patented Directional Genomic Hybridization (dGH) technology, KromaTiD's assays generate sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies. Founded in 2007 and headquartered in Fort…
About
Business model
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Hybridization-based > Microarrays,
Life Sciences Platforms and Tools > Research Assays > Drug Discovery > Microarrays
Institutional investors
Broadoak Capital PartnersNHGRIFirst Capital VenturesHHSCID4Innosphere
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.